See also Phosphodiesterase type III inhibitors

General information

Enoximone is an inhibitor of phosphodiesterase type III, and has a positive inotropic effect. Its most common adverse effects are gastrointestinal and cardiac. The gastrointestinal effects include anorexia, nausea, vomiting, and diarrhea [ , ].

Other rarely reported adverse effects include thrombocytopenia, leukocytosis, increased appetite, increased serum activity of alanine transaminase, hyperglycemia, headache, lethargy, anxiety, dyspnea, and rashes [ ].

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here